{
    "nct_id": "NCT05528133",
    "official_title": "Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer",
    "inclusion_criteria": "* Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection\n* Confirmation of Triple Negative (TN) breast cancer by tissue biopsy\n* Adequate tissue to calculate RSI\n* To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines\n* To fulfill the requirement of hormone receptor (HR)- disease, a breast cancer must express (<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines\n* Life expectancy >16 weeks\n* KPS ≥ 70\n* Age ≥ 18 years\n* Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon\n* There is no limit on prior systemic therapies\n* Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study\n* Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation\n* Women who are pregnant or breastfeeding\n* Positive surgical margins\n* History of allergy or hypersensitivity to any of the study drugs or study drug components\n* Metastatic breast cancer",
    "miscellaneous_criteria": ""
}